The clinical relevance of azithromycin's tissue-to-plasma concentration ratio being >100:1 in most tissues, with intracellular concentrations especially high in phagocytes, is that:

• A This extremely high tissue distribution reduces its plasma half-life to less than 4 hours, requiring twice-daily dosing
• B The high intraphagocyte concentration means azithromycin is effective against MRSA through phagocyte-mediated drug delivery
• C High tissue concentrations cause dose-dependent hepatotoxicity at tissues even at standard doses
• D Azithromycin achieves very high concentrations at intracellular infection sites (Chlamydia, Legionella, Mycoplasma) and delivers drug to infected tissues via phagocyte trafficking, explaining its efficacy despite low serum levels ✓

Explanation

Azithromycin's extraordinarily high volume of distribution (31 L/kg) and intracellular accumulation in phagocytes (PMNs, macrophages) is pharmacokinetically unique. Phagocytes concentrate azithromycin 200-2000 fold over plasma and transport it to sites of infection, releasing it during phagocytosis — effectively using cells as drug delivery vehicles to infection loci. This explains its clinical efficacy against obligate intracellular pathogens (Chlamydia, Legionella, Mycoplasma) that cannot be reached by hydrophilic drugs. The very long terminal half-life (~68 hours) actually results from slow tissue release; the 5-day course achieves tissue concentrations persisting for 7–10 days.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.